Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Stefan Hildbrand is active.

Publication


Featured researches published by Stefan Hildbrand.


Journal of Medicinal Chemistry | 2008

Benzodioxoles: Novel Cannabinoid-1 Receptor Inverse Agonists for the Treatment of Obesity

Leo Alig; Jochem Alsenz; Mirjana Andjelkovic; Stefanie Bendels; Agnès Bénardeau; Konrad Bleicher; Anne Bourson; Pascale David-Pierson; Wolfgang Guba; Stefan Hildbrand; Dagmar Kube; Thomas Lübbers; Alexander V. Mayweg; Robert Narquizian; Werner Neidhart; Matthias Nettekoven; Jean-Marc Plancher; Cynthia Rocha; Mark Rogers-Evans; Stephan Röver; Gisbert Schneider; Sven Taylor; Pius Waldmeier

The application of the evolutionary fragment-based de novo design tool TOPology Assigning System (TOPAS), starting from a known CB1R (CB-1 receptor) ligand, followed by further refinement principles, including pharmacophore compliance, chemical tractability, and drug likeness, allowed the identification of benzodioxoles as a novel CB1R inverse agonist series. Extensive multidimensional optimization was rewarded by the identification of promising lead compounds, showing in vivo activity. These compounds reversed the CP-55940-induced hypothermia in Naval Medical Research Institute (NMRI) mice and reduced body-weight gain, as well as fat mass, in diet-induced obese Sprague-Dawley rats. Herein, we disclose the tools and strategies that were employed for rapid hit identification, synthesis and generation of structure-activity relationships, ultimately leading to the identification of (+)-[( R)-2-(2,4-dichloride-phenyl)-6-fluoro-2-(4-fluoro-phenyl)-benzo[1,3]dioxol-5-yl]-morpholin-4-yl-methanone ( R)-14g . Biochemical, pharmacokinetic, and pharmacodynamic characteristics of ( R)-14g are discussed.


Chimia | 2018

Efficient Industrial Synthesis of the MDM2 Antagonist Idasanutlin via a Cu(I)-catalyzed [3+2] Asymmetric Cycloaddition

Dan Fishlock; Ralph Diodone; Stefan Hildbrand; Bernd Kuhn; Christian Mössner; Carsten Peters; Pankaj D. Rege; Gösta Rimmler; Markus Schantz.

A concise asymmetric synthesis has been developed to prepare idasanutlin, a small molecule MDM2 antagonist. Idasanutlin is currently being investigated as a potential treatment for various solid tumors and hematologic malignancies. The highly congested pyrrolidine core, containing four contiguous stereocenters, was constructed via a Cu(I)/(R)-BINAP catalyzed [3+2]-cycloaddition reaction. This optimized copper(I)-catalyzed process has been used to produce more than 1500 kg of idasanutlin. The manufacturing process will be described, highlighting the exceptionally selective and consistent cycloaddition/isomerization/hydrolysis sequence. The excellent yields, short cycle times and reduction in waste streams result in a sustainable production process with low environmental impact.


Archive | 2007

Process for the preparation of pyrido[2,1-a]isoquinoline derivatives comprising optical resolution of an enamine

Stefan Abrecht; Jean-Michel Adam; Alec Fettes; Stefan Hildbrand


Archive | 2012

Process for the manufacture of pharmaceutically active compounds

Stefan Hildbrand; Hans-Juergen Mair; Roumen Nikolaev Radinov; Yi Ren; James Anderson Wright


Archive | 2007

Process for the preparation of 4'-Azido cytidine derivatives

Peter John Harrington; Stefan Hildbrand; Keshab Sarma


Organic Process Research & Development | 2011

An Efficient Process for the Manufacture of Carmegliptin

Stefan Abrecht; Jean-Michel Adam; Ulrike Bromberger; Ralph Diodone; Alec Fettes; Rolf Fischer; Volker Goeckel; Stefan Hildbrand; Gérard Moine; Martin Weber


Archive | 2008

Process for the preparation of pyrido [2, 1-a] isoquinoline derivatives and polymorphic froms thereof

Ulrike Bromberger; Ralph Diodone; Stefan Hildbrand; Roland Meier


Archive | 2006

Method of preparation of pure 4-pyrrolidinophenylbenzyl ether derivatives as maob inhibitors

Stefan Hildbrand; Bruno Lohri; Wolfgang Wostl


Organic Process Research & Development | 2016

Practical Synthesis of MDM2 Antagonist RG7388. Part 2: Development of the Cu(I) Catalyzed [3 + 2] Asymmetric Cycloaddition Process for the Manufacture of Idasanutlin

Gösta Rimmler; André Alker; Marcello Bosco; Ralph Diodone; Dan Fishlock; Stefan Hildbrand; Bernd Kuhn; Christian Moessner; Carsten Peters; Pankaj D. Rege; Markus Schantz.


Archive | 2013

PROCESS FOR THE PREPARATION OF 2-DEOXY-2-FLUORO-2-METHYL-D-RIBOFURANOSYL NUCLEOSIDE COMPOUNDS

Robert Carr; Stefan Hildbrand; L. Mark Hodges; Michael Kammerer; John F. Lang; William J. Lawrimore; Dieu Nguyen

Collaboration


Dive into the Stefan Hildbrand's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge